| Pazopanib hydrochloride, paclitaxel, and carboplatin in treating patients with refractory or resistant EOC | 1, 2 | Pazopanib in combination with paclitaxel and carboplatin chemotherapy | Platinum-refractory or resistant EOC | PFS |
| Trametinib in treating patients with recurrent or progressive low-grade ovarian cancer | 2, 3 | Trametinib PO QD on days 1 - 28, every 28 days | Low-grade serous ovarian carcinoma that recur as low-grade serous carcinoma | PFS |
| Pazopanib and weekly topotecan in patients recurrent ovarian cancer (TOPAZ) | 1, 2 | Topotecan weekly 3 - 4 mg/m2, pazopanib 400, 600, 800 mg according to dose level | Platinum resistant or refractory or intermediate platinum-sensitive (recurrence within 12 months after a platinum-based primary therapy) EOC disease | PFS |
| A randomized study of safety and efficacy of pazopanib and gemcitabine in persistent or relapsed ovarian cancer | 2 | Gemcitabine 1000 mg/m2 on days 1, 8 up to 6 cycles. Pazopanib 800 mg PO daily on days 1 - 21 | Relapsed ovarian cancer previously with carboplatin, cisplatin or another organo-platinum compound | PFS |